Abbreviations: Immuno-oncology (I/O), B-cell non-Hodgkin lymphoma (B-NHL), relapsed or refractory (r/r), recurrent or metastatic (r/m), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), neurotrophic tropomyosin receptor kinase (NTRK).

Notes: The trademarks and registered trademarks within are the property of their respective owners. *Greater China-only trials. **Greater China trial in preparation or under planning. Greater China = mainland China, Hong Kong, Macau and Taiwan. (1) Also launched in Hong Kong and Macau; (2) Including non-small cell lung cancer; (3) Commercially available in Hong Kong; (4) Also approved in Hong Kong and Taiwan; (5) FDA accelerated approval; continued approval may be contingent on verification and confirmation of clinical benefit in confirmatory trials; (6) Combination with carboplatin and KEYTRUDA +/- bevacizumab; (7) 1st line+ locally advanced or metastatic disease in solid tumors including colorectal cancer, pancreatic cancer, non-small cell lung cancer, and head and neck cancer; monotherapy and combination with KEYTRUDA and either carboplatin or cisplatin; (8) FDA accelerated approval of KRAZATI for 2L+ NSCLC with KRAS G12C mutation in December 2022; (9) NDA acceptance by the NMPA in January 2022; (10) Global Ph3 trial initiated; (11) Global Ph1/2a trial ongoing;(12) Zai Lab has exclusive license to develop and commercialize SUL-DUR in mainland China, Hong Kong, Taiwan, Macau, Korea, Vietnam, Thailand, Cambodia, Laos, Malaysia, Indonesia, the Philippines, Singapore, Australia, New Zealand, and Japan; (13) Initiated enrollment of two proof-of-concept trials in autoimmune renal diseases in China in February 2023; (14) Achieved proof of concept of Ph1b study in October 2021.

For more information about the above trials, please visit https://clinicaltrials.gov